KR20210113271A - 콜라게나제 제형 및 이의 제조 방법 - Google Patents
콜라게나제 제형 및 이의 제조 방법 Download PDFInfo
- Publication number
- KR20210113271A KR20210113271A KR1020217024557A KR20217024557A KR20210113271A KR 20210113271 A KR20210113271 A KR 20210113271A KR 1020217024557 A KR1020217024557 A KR 1020217024557A KR 20217024557 A KR20217024557 A KR 20217024557A KR 20210113271 A KR20210113271 A KR 20210113271A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- collagenase
- lyophilized
- lys
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788916P | 2019-01-06 | 2019-01-06 | |
| US62/788,916 | 2019-01-06 | ||
| PCT/US2020/012202 WO2020142701A1 (en) | 2019-01-06 | 2020-01-03 | Collagenase formulations and methods of producing the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267010947A Division KR20260051486A (ko) | 2019-01-06 | 2020-01-03 | 콜라게나제 제형 및 이의 제조 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210113271A true KR20210113271A (ko) | 2021-09-15 |
Family
ID=69845512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217024557A Ceased KR20210113271A (ko) | 2019-01-06 | 2020-01-03 | 콜라게나제 제형 및 이의 제조 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20220305094A1 (https=) |
| EP (1) | EP3906014A1 (https=) |
| JP (2) | JP7565280B2 (https=) |
| KR (1) | KR20210113271A (https=) |
| CN (1) | CN113382714A (https=) |
| AU (2) | AU2020204922B2 (https=) |
| BR (1) | BR112021012675A2 (https=) |
| IL (2) | IL321891A (https=) |
| MX (1) | MX2021008017A (https=) |
| WO (1) | WO2020142701A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172070A1 (ko) * | 2022-03-08 | 2023-09-14 | 주식회사 코넥스트 | 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113025599B (zh) * | 2021-04-02 | 2023-09-12 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 |
| CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
| CN114264633B (zh) * | 2022-02-10 | 2022-09-06 | 上海蓝长科技集团有限公司 | 一种福尔马肼聚合物冻干粉及制备方法 |
| CN119656117B (zh) * | 2024-12-18 | 2025-08-29 | 远大生命科学(鞍山)有限公司 | 一种药物组合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2921180B1 (en) * | 1999-02-22 | 2019-08-14 | University of Connecticut | Albumin-free factor VIII formulations |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| CN101312744A (zh) | 2005-11-22 | 2008-11-26 | 惠氏公司 | 免疫球蛋白融合蛋白制剂 |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| ES2388219T3 (es) * | 2008-06-02 | 2012-10-10 | F. Hoffmann-La Roche Ag | Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| JP2014530873A (ja) * | 2011-10-21 | 2014-11-20 | オーキシリウム インターナショナル ホールディングス,インコーポレイテッド | Efpの治療または低減方法 |
| PT2802652T (pt) | 2012-01-12 | 2019-09-10 | Endo Global Ventures | Enzimas de clostridium histolyticum |
| EP3834840B8 (en) | 2013-03-15 | 2025-09-17 | Endo Biologics Limited | Treatment method and product for uterine fibroids using purified collagenase |
| US10137179B2 (en) * | 2016-05-18 | 2018-11-27 | Hyalo Technologies, LLC | Composition and method of preparation of protease microparticulate slow release preparation |
| CA3039655A1 (en) * | 2016-10-07 | 2018-04-12 | Regeneron Pharmaceuticals, Inc. | Room temperature stable lyophilized protein |
| EP4591945A3 (en) * | 2017-03-01 | 2026-04-15 | Endo Operations Limited | Apparatus and method for assessing and treating cellulite |
-
2020
- 2020-01-03 US US17/419,899 patent/US20220305094A1/en not_active Abandoned
- 2020-01-03 AU AU2020204922A patent/AU2020204922B2/en active Active
- 2020-01-03 WO PCT/US2020/012202 patent/WO2020142701A1/en not_active Ceased
- 2020-01-03 IL IL321891A patent/IL321891A/en unknown
- 2020-01-03 BR BR112021012675-9A patent/BR112021012675A2/pt active Search and Examination
- 2020-01-03 MX MX2021008017A patent/MX2021008017A/es unknown
- 2020-01-03 KR KR1020217024557A patent/KR20210113271A/ko not_active Ceased
- 2020-01-03 CN CN202080010875.3A patent/CN113382714A/zh active Pending
- 2020-01-03 JP JP2021539410A patent/JP7565280B2/ja active Active
- 2020-01-03 IL IL284270A patent/IL284270B2/en unknown
- 2020-01-03 EP EP20712071.8A patent/EP3906014A1/en active Pending
-
2023
- 2023-09-29 US US18/478,368 patent/US12303557B2/en active Active
-
2024
- 2024-09-30 JP JP2024169863A patent/JP2025016453A/ja active Pending
-
2025
- 2025-04-22 US US19/185,838 patent/US20250249080A1/en active Pending
- 2025-06-30 AU AU2025204915A patent/AU2025204915A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172070A1 (ko) * | 2022-03-08 | 2023-09-14 | 주식회사 코넥스트 | 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법 |
| US12516310B2 (en) | 2022-03-08 | 2026-01-06 | CONNEXT Co., Ltd | Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022516569A (ja) | 2022-02-28 |
| IL321891A (en) | 2025-09-01 |
| AU2025204915A1 (en) | 2025-07-24 |
| AU2020204922B2 (en) | 2025-04-24 |
| IL284270A (en) | 2021-08-31 |
| JP7565280B2 (ja) | 2024-10-10 |
| MX2021008017A (es) | 2021-08-05 |
| CN113382714A (zh) | 2021-09-10 |
| JP2025016453A (ja) | 2025-02-04 |
| BR112021012675A2 (pt) | 2021-09-28 |
| CA3125007A1 (en) | 2020-07-09 |
| US20250249080A1 (en) | 2025-08-07 |
| WO2020142701A1 (en) | 2020-07-09 |
| US20240041993A1 (en) | 2024-02-08 |
| US20220305094A1 (en) | 2022-09-29 |
| IL284270B1 (en) | 2025-08-01 |
| US12303557B2 (en) | 2025-05-20 |
| AU2020204922A1 (en) | 2021-07-01 |
| EP3906014A1 (en) | 2021-11-10 |
| IL284270B2 (en) | 2025-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210113271A (ko) | 콜라게나제 제형 및 이의 제조 방법 | |
| JP6258674B2 (ja) | クロストリジウム・ディフィシレトキソイドaおよびbを含有する薬学的組成物 | |
| AU2021250949A1 (en) | Liquid Pharmaceutical Composition | |
| Hackl et al. | Effect of arginine on the aggregation of protein in freeze-dried formulations containing sugars and polyol: 1—formulation development | |
| KR20260051486A (ko) | 콜라게나제 제형 및 이의 제조 방법 | |
| CN121335712A (zh) | 用于产生包含多克隆IgM的冻干组合物的方法及获得的组合物 | |
| TWI827694B (zh) | 免疫蛋白酶體抑制劑調配物 | |
| Bjelošević et al. | Effects of monoclonal antibody concentration and type of bulking agent on critical quality attributes of lyophilisates | |
| CA3125007C (en) | Collagenase formulations and methods of producing the same | |
| HK40053714A (en) | Collagenase formulations and methods of producing the same | |
| US20250235515A1 (en) | Clostridium botulinum neurotoxin serotype a compositions and improved drying processes | |
| JP2023526024A (ja) | Il-2融合ポリペプチド組成物ならびにその作製及び使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| V11 | Administrative appeal requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE) |